.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DH55_PanipenemAndBetamipron.PanipenemAndBetamipron .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DH55_PanipenemAndBetamipron.PanipenemAndBetamipron| name: | PanipenemAndBetamipron | |
| ATC code: | J01DH55 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 500 | mg |
| volume of distribution: | 8.5 | L |
| clearance: | 10.5 | L/h |
| other parameters in model implementation | ||
Panipenem and betamipron is a combination of a carbapenem antibiotic (panipenem) and a renal dehydropeptidase inhibitor (betamipron). The combination is used to treat a variety of bacterial infections, especially those caused by resistant Gram-negative organisms. Betamipron reduces nephrotoxicity by inhibiting the renal uptake of panipenem. This combination is not approved in the US or EU but is used in some countries, notably Japan.
Pharmacokinetics reported in healthy adult Japanese volunteers after intravenous administration.
Tajima, N, et al., & Naganuma, H (2005). Quantitative evaluation of effect of renal failure on the pharmacokinetics of panipenem in rats. Biological & pharmaceutical bulletin 28(11) 2170–2172. DOI:10.1248/bpb.28.2170 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16272714